Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pregnancy-specific beta-1-glycoprotein 9 (PSG9)
- Target
- PSG9
- Molecular classification
- Immunoglobulin superfamily protein, Secreted glycoprotein, Member of the carcinoembryonic antigen cell adhesion molecule (CEACAM) gene family
01
Overview
Pregnancy-specific beta-1-glycoprotein 9 (PSG9) is a heavily glycosylated, secreted member of the immunoglobulin superfamily, encoded by the PSG gene cluster and predominantly expressed in placental tissue. It contributes to fetal-maternal immune tolerance and maintenance of pregnancy. Pathologically, PSG9 is significantly upregulated in breast and colorectal tumors, functioning as a transcriptional target and amplifier of the canonical TGF-β/Smad pathway. PSG9 promotes cancer cell proliferation, migration, invasion, and angiogenesis by stabilizing Smad2, Smad3, and Smad4 proteins and regulating EMT-related genes. It is present in both cytoplasm and nucleus of target cells and directly interacts with Smad proteins. Clinically, PSG9 serves as a non-invasive plasma biomarker for early detection and prognosis of certain cancers, but no clinically approved therapeutic drugs target PSG9 to date[1][2][3][4][5].
- Other names
- Pregnancy-specific beta-1-glycoprotein 9PSG9PSBG-9PS-beta-G-9PS-beta-BPregnancy-specific glycoprotein 9
02
Mechanism of action
Drugs theoretically targeting PSG9 would aim to block its role in stabilizing Smad proteins and activating TGF-β/Smad signaling, thereby inhibiting cancer cell growth, migration, and EMT
03
Biological functions
Maintenance of normal gestationRegulation of epithelial-mesenchymal transition (EMT)Regulation and amplification of TGF-β/Smad signalingImmune modulation (e.g., activation of TGF-β1, induction of regulatory T cells, suppression of pro-inflammatory cytokines)Inhibition of platelet-fibrinogen interactions
04
Disease associations
Cancer — especially breast and colorectal cancer (migration, proliferation, angiogenesis, poor prognosis)Gestational trophoblastic neoplasmsImmune-related fetal growth restriction
05
Safety considerations
Potential concerns with targeting include undesired modulation of immune tolerance during pregnancy or thrombotic homeostasis
06
Interacting drugs
None documented as approved; however, its interaction with the TGF-β pathway and potential as a target for antibody drugs or TGF-β inhibitors is under investigation
07
Biomarkers
Elevated plasma PSG9 — biomarker for metastatic breast cancer, colorectal carcinogenesis, poor prognosis
Beyond the preview
Go deeper on Pregnancy-specific beta-1-glycoprotein 9 (PSG9).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pregnancy-specific beta-1-glycoprotein 9 (PSG9).